Trial Profile
An Open-label Extension Study of Subcutaneously Administered Fitusiran in Patients With Moderate or Severe Hemophilia A or B Who Have Participated in a Previous Clinical Study With Fitusiran
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Fitusiran (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals; Sanofi Genzyme
- 12 Dec 2023 Results of pooled analysis from Phase 1 (NCT02035605), Phase 1/2 (NCT02554773) and Phase 3 studies (NCT03417102, NCT03417245, NCT03549871) in PwH A/B, with or without inhibitors, PopPK/PD model, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 03 Apr 2023 Status changed from active, no longer recruiting to completed.
- 04 Aug 2022 Planned End Date changed from 21 Jun 2023 to 4 Apr 2023.